An interventional study of SBRT in OligoProgressive Metastatic Disease, sponsored by Jules Bordet Institute. Recruiting at 5 sites in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Jules Bordet Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is the 20th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 with no phase, and was the 40th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:
Jules Bordet Institute · Sites in Belgium
Ages 18–70 · Women only
Jules Bordet Institute · Sites in Belgium
Ages 18+ · Women only
Jules Bordet Institute · Sites in Belgium, Germany, Iceland and 7 more countries
Ages 18+
Jules Bordet Institute
Ages 18+
Jules Bordet Institute
Ages 18–40 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 1
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 49 across the 38 interventional studies, 1,200 across the 4 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jules Bordet Institute is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
1 of the studies in Breast Neoplasms by Jules Bordet Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06150898Jules Bordet InstituteKetorolac and Pregabalin Effects on breaSt Cancer (KePreSt) | 2027-04-20 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3 extracranial metastases, which are treatable locally. The trial aims to investigate if treating these resistant metastases with SBRT (or other local treatments if SBRT is not possible) can extend the use of the current systemic therapy.
Patients will continue their existing systemic treatment while receiving SBRT on all progressive lesions. If new oligoprogression occurs, SBRT will be performed again. A new systemic treatment line will start if there is polyprogression (more than 3 lesions at once), progression of more than 6 lesions over 12 months, intracranial progression, or lesions that cannot be treated locally.
The scientific question is whether local treatment of resistant metastases can prolong the effectiveness of ongoing systemic therapy, which is particularly beneficial if the treatment is well-tolerated. The primary objective is to measure the proportion of patients surviving without changing their systemic treatment line at 6 months after SBRT.
This trial is significant for patients as it explores a method to potentially extend the duration of effective and well-tolerated treatments, offering hope for better management of metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: SBRT
SBRT of all oligoprogressive metastases (or other local therapy if SBRT not advisable), followed by continuation of the same systemic therapy.
NExt Systemic Treatment-Free Survival (NEST-FS)
Time frame: At 6 months
Time to next line of systemic therapy (NEST)
Time frame: 3 years
Progression-free survival (PFS)
Time frame: 3 years
Modified Progression-free survival (mPFS)
Defined as the survival in the absence of any of the following : (1) polyprogression (progressive disease of more than 3 lesions at the same time), (2) progression of more than 6 lesions over a 12-month rolling period, (3) intracranial progression, (4) progressing lesion that cannot be treated locally, or (5) death.
Time frame: 3 years
Chemotherapy-free survival
Time frame: 3 years
Progression-free survival after start of the subsequent line of systemic treatment (PFS2)
Time frame: 3 year
Patterns of metastatic progression
We defined four patterns of progression: stable disease, progression on untreated pre-existing lesions, progression on treated lesions, or development of new lesions. In case of progression, it will also be determined whether it is oligoprogression (progression of 3 lesions or less) or polyprogression (progression of more than 3 lesions).
Time frame: 3 years
Overall survival (OS)
Time frame: 3 years
Acute and late physician-scored toxicity of the local intervention
Acute and late physician-scored toxicity of the local intervention (CTCAE 5.0, Early: within 90 days; late: 90 or more days after SBRT);
Time frame: 3 years
Quality of life (QoL)
Evolution of QoL measured with the EORTC QLQ-C30
Time frame: 3 years
Correlation between (1) ctDNA burden at baseline and (2) ctDNA burden 10-12 weeks after SBRT versus the modified progression-free-survival (mPFS). NEST-FS in function of ESR1 status.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for May 2028, 30 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 30 months is close to that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.